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Abstract. Inadequate pain management 
but also inappropriate use of analgesics in 
early infancy has negative effects on neuro-
developmental outcome. As a consequence, 
neonatal pain management is still in search 
for the Holy Grail. At best, effective pain 
management is based on prevention, assess-
ment, and treatment followed by a re-assess-
ment of the pain to determine if additional 
treatment is still necessary. Unfortunately, 
epidemiological observations suggest that 
neonates are undergoing painful procedures 
very frequently, unveiling the need for effec-
tive preventive, non-pharmacological strate-
gies. In addition, assessment is still based on 
validated, multimodal, but subjective pain 
assessment tools. Finally, in neonatal in-
tensive care units, there is a shift in clinical 
practices (e.g., shorter intubation and ven-
tilation), and this necessitates the develop-
ment and validation of new pharmacological 
treatment modalities. To illustrate this, a shift 
in the use of opioids to paracetamol has oc-
curred and short-acting agents (remifentanil, 
propofol) are more commonly administered 
to neonates. In addition to these new modali-
ties and as part of a more advanced approach 
of the developmental pharmacology of anal-
gesics, pharmacogenetics also emerged as a 
tool for precision medicine in neonates. To 
assure further improvement of neonatal pain 
management the integration of pharmacoge-
netics with the usual covariates like weight, 
age and/or disease characteristics is needed.
Introduction: on how we act 
and what we know
Inadequate pain management in neonatal 
life impairs neurodevelopmental outcome. 
It alters pain thresholds, physiological re-
sponses and stress- or pain-related behavior 
beyond early infancy [1, 2, 3, 4]. Therefore, 
pain management in neonates should not 
just be driven by ethics or empathy but it 
should be viewed as part of normal medical 
and nursing care. At the same time, there are 
emerging animal experimental and human 
epidemiological data that show an associa-
tion between the exposure to analgesics and 
impaired neurodevelopmental outcome [5, 
6, 7]. As a consequence, the management of 
neonatal pain remains in search of a new bal-
ance because these conflicting observations 
are the main drivers to tailor our current prac-
tices. To reach this new balance new treatment 
modalities, including non-pharmacological 
and pharmacological strategies, will need to 
be developed and validated [7, 8, 9].
Epidemiology
An additional argument in support of the 
need for new treatment modalities, including 
non-pharmacological interventions, is that 
epidemiological observations provide evi-
dence for shifts in neonatal pain management 
practices [10]. In Table 1, we summarized 
observations on pain management practices 
in (pre)term neonates in the first 14 days of 
postnatal life [11, 12, 13]. Compared to the 
cohorts of 2001 and 2005 – 2006, the Rotter-
dam group (2009) documented a statistically 
significant, but clinically modest decrease 
in the number of painful procedures (11 in-
stead of 14/day) [11, 13], with more routine 
use and integration of non-pharmacological 
interventions, and a decrease in opioid use in 
ventilated newborns [13].
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Pain management in neonates is not 
only limited to pharmacological 
interventions
Non-pharmacological interventions stress 
the fact that not only what, but also how we 
perform painful procedures matters [8, 9, 
14]. The focus needs to be on less invasive 
techniques, preventive strategies, or comple-
mentary techniques [14, 15]. Environmental 
(light or noise exposure), behavioral (posi-
tioning, handling, swaddling), and non-phar-
macological (sucrose, breastfeeding, pacifier, 
non-nutritive sucking) interventions prevent, 
alleviate, or even eliminate pain. Adaptations 
of procedural practices may be a very power-
ful approach to prevent pain. Such strategies 
also cover the use of central venous catheters 
instead of multiple peripheral perfusions, in-
dividualized monitoring techniques (blood 
pressure measurement interval, vital signs 
registration), adapted nursing techniques 
(e.g., frequency of endotracheal suction-
ing, skin and wound care, tape and wound 
dressing) or promoting skin-to-skin contact 
between newborn and parents [8, 9, 14, 15].
Assessment is still subjective and 
thus suboptimal
The absence of verbalization is very 
likely one of the most important thresholds 
for the proper diagnosis and management of 
neonatal pain [16, 17, 18]. Pain in the new-
born is not easily recognized and remains 
commonly under- or untreated. Pain assess-
ment is still based on validated, multimodal, 
but subjective pain assessment tools, like 
the COMFORTneo score [17]. Until more 
advanced equipment becomes available to 
quantify pain, we should apply such a vali-
dated pain assessment tool in clinical prac-
tice and train health care providers in using 
these tools in a standardized way to guaran-
tee a reasonable interobserver variation in 
the assessment of pain in neonates [18, 19].
Developmental pharmacology 
of analgesics in neonates: 
a moving target
The general paradigm on pain manage-
ment in neonates is driven by assessment, 
titration of a given intervention (non-phar-
macological, pharmacological, or both) and 
subsequent re-assessment [3, 8]. Clinical 
pharmacology aims to predict (side) effects 
of compound specific pharmacokinetics 
(PK) and pharmacodynamics (PD) at the 
level of the population or – preferably – the 
individual. These general concepts of clini-
cal pharmacology obviously also apply to 
analgesics in neonates, but their maturation-
al physiology and the associated variabil-
ity within the population warrant a tailored 
approach [20, 21, 22]. PK in early infancy 
display extensive intra- and inter-individual 
variability. This can in part be explained by 
e.g., maturational changes in body composi-
tion, protein binding, and compartment sizes 
during infancy. Similar, drug-related meta-
bolic processes mature in an enzyme-specific 
pattern while renal function also displays an 
age-dependent increase in clearance. From a 
clinical pharmacology perspective, the con-
sequence of such a dynamic setting is exten-
sive variability in early infancy [20, 21, 22].
This dynamic setting further stresses the 
need to perform focused studies on new an-
algesics introduced in the neonatal unit [22]. 
Moreover, it also means that new covariates 
emerging in other populations such as phar-
Table 1. The incidence of painful procedures and its management as reported in different cohorts of 
(pre)term neonates. All studies collected data in the first 14 days of postnatal life [11, 12, 13].
Rotterdam [11] Paris [12] Rotterdam [13]
Time interval of data collection 2001 2005 – 2006 2009
Number of patients 151 430 175
Gestational age (weeks) 32.4 (SD 4.5) 33 (SD 4.6) 31.6 (range 24 – 41)
Patient days 1,375 3,598 1,730
Number of procedures, total 19,674 42,413 21,076
Number of procedures, per day 14.3 (SD 4.0) 16 (SD 9) 11.4 (SD 5.7)
Pharmacological analgesia (%) 60.3% 57.1% 36.5%
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macogenetics may further explain in part the 
variability observed in neonates, but need to 
be integrated with other maturational covari-
ates like weight or age. We will first discuss 
the PK/PD of intravenous paracetamol and 
two short acting compounds (remifentanil, 
propofol) since these drugs have recently 
been introduced in neonatal intensive care 
units. Then we will provide guidance on how 
to integrate pharmacogenetics as another co-
variate to improve the predictability of indi-
vidual PK or PD in early infancy.
Shift from opioids to paracetamol
In an attempt to avoid or reduce opioid 
exposure, a shift to administer paracetamol 
has occurred, hugely facilitated by the avail-
ability of an intravenous formulation [23, 24, 
25, 26, 27]. Despite the fact that intravenous 
paracetamol is still used off label in specific 
subpopulations (e.g., limited to term neo-
nates, or, under 2 years of age in the United 
States), these formulations are increasing-
ly used in (pre)term neonates [23, 26]. In 
adults, paracetamol is metabolized by the 
liver to paracetamol-glucuronide (47 – 62%) 
and paracetamol-sulphate (25 – 36%), and 
subsequently eliminated by the renal route. 
Only 1 – 4% is excreted unchanged in urine, 
and ~ 8 – 10% of paracetamol is oxidized 
to 3-hydroxy-paracetamol and the (hepatic) 
toxic metabolite N-acetyl-p-benzoquinone-
imine (NAPQI). In neonates, paracetamol 
clearance is lower, and its variability is 
mainly explained by weight. This is further 
illustrated in Figure 1, where we plotted the 
individual paracetamol clearance estimates 
for 30 (pre)term neonates following a single 
intravenous paracetamol administration [28]. 
Similarly, also the formation clearance to 
paracetamol-glucuronide and paracetamol-
sulphate, and primary renal elimination of 
paracetamol is mainly related to weight [29]. 
However, in contrast to the observations in 
adults, sulphation and not glucuronidation 
is the most important route of elimination in 
neonates [29].
The currently available evidence on the 
efficacy of paracetamol as analgesic supports 
the use of paracetamol for minor to moder-
ately severe pain syndromes in early infancy 
[30]. Moreover, paracetamol has a clinically 
relevant opioid-sparing effect (66%) in neo-
nates after major non-cardiac surgery [24]. 
In contrast, there is only a very limited an-
algesic effect of paracetamol when used for 
procedural (e.g., heel lancing) pain relief 
[23]. Short-term tolerance (hepatic, hemo-
dynamics) has been described [31, 32], indi-
cating no signs of hepatic intolerance during 
and after repeated administrations of intra-
venous paracetamol [31]. In contrast to the 
negative hemodynamic effects in adult in-
tensive care patients, hemodynamic side ef-
fects of intravenous paracetamol in neonates 
are very modest [32]. Besides these short-
term outcome side effects, there are some 
population-specific side effects that warrant 
focused attention. Recent epidemiological 
data showed a possible link between the 
(over) use of paracetamol during pregnancy 
or early infancy and immune deviations or 
neurodevelopmental problems (e.g., autism) 
[23]. Causality is still very questionable and 
for sure not yet proven, but pharmacovigi-
lance is warranted to explore the potential as-
sociation between paracetamol exposure and 
these outcome variables.
Figure 1. Individual clearance (L/kg/h) estimates 
in 30 (pre)term neonates following a single intra-
venous propacetamol (10 – 20 mg/kg paracetamol 
equivalent) administration show a modest increase 
with increasing weight (median clearance < 2 kg 
0.123 to 0.16 L/kg/h in cases > 2 kg) (X-axis: 
weight, in g; Y-axis: paracetamol clearance, in L/
kg/h) [28].
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The need to generate knowledge 
of short-acting agents in 
neonates
Taking the shift towards less invasive 
neonatal care (e.g., insure procedure, i.e., 
intubation – surfactant administration – ex-
tubation instead of prolonged mechanical 
ventilation) into account, remifentanil and 
propofol have been introduced in neonatal 
intensive care [2, 8, 9, 33, 34].
Remifentanil hydrochloride is a short-
acting, µ-receptor opioid agonist. It achieves 
its peak analgesic effect within a minute 
of administration, 3 – 4 times faster when 
compared to fentanyl and much faster when 
compared to morphine [33]. Remifentanil 
undergoes metabolic clearance by plasma 
esterases, resulting in predictable clearance, 
irrespective of renal or liver dysfunction, and 
the plasma esterase activity is already quite 
mature at birth [35]. Its pharmacological pro-
file seems suited for short procedural anal-
gesia [36, 37, 38, 39, 40]. In neonates, this 
compound has mainly been used for short 
procedures like endotracheal intubation, la-
ser surgery for retinopathy of prematurity or 
for insertion of a percutaneous intravenous 
central catheter with anecdotal experience 
during major surgery or mechanical ventila-
tion [36, 37, 38, 39, 40]. Because of its rapid 
clearance, clinicians must be aware that the 
analgesic effects disappear very soon after 
discontinuation of remifentanil [33]. Other 
issues to consider are potential hyperalgesia, 
fast appearance of tolerance, and the risk of 
chest rigidity [33].
Propofol (2,6 di-isopropylphenol) is a 
highly lipophilic compound [34]. Propofol 
exhibits rapid distribution to the subcutane-
ous fat and the central nervous system com-
partments with subsequent redistribution to 
the blood compartment and metabolic clear-
ance [34, 41]. Because propofol is not soluble 
in water, propofol clearance is exclusively 
through metabolic clearance [41, 42]. Al-
though multiple hepatic and extrahepatic hu-
man cytochrome (CYP) P450 isoforms (hy-
droxylation, mainly CYP2B6) are involved 
in propofol metabolism, glucuronidation is 
the major metabolic pathway after a single 
intravenous bolus in adults [41, 42, 43]. In 
contrast, propofol clearance in neonates is 
much lower, and mainly driven by postnatal 
age [43]. Interestingly and based on 24 hours 
urine collections, not glucuronidation but 
hydroxylation is the most important route of 
propofol metabolism in the first 10 days of 
postnatal life [42, 43]. In neonates, there is 
reported experience with intravenous bolus 
propofol administration to facilitate endotra-
cheal intubation, but there is important vari-
ability in clinical characteristics, outcome 
criteria, comedication and doses evaluated in 
the different studies [34, 44, 45]. Similarly, 
there is conflicting information on the mag-
nitude of hemodynamic (side) effects of pro-
pofol in (pre)term neonates. In a recent Co-
chrane review, Shah et al. [34] concluded that 
regarding the use of propofol in neonates, no 
practice recommendations could be made yet.




The emerging field of pharmacogenetics 
as a tool for personalized medicine – includ-
ing pain management – reflects the notion 
that a specific (side) effect is not at random 
distributed in a specific population [46]. This 
obviously also holds promises for personal-
ized pain management in young infants, but 
in addition to the usual covariates like weight, 
age and/or disease characteristics [22, 47]. We 
hereby strongly recommend the integration of 
pharmacogenetics as an additional covariate 
to improve individual PK or PD predictions in 
early infancy [22, 47]. In this special issue on 
various aspects of pain and its management, 
pharmacogenetics is repeatedly suggested to 
contribute to the PK/PD variability of analge-
sics. We will illustrate the complex interaction 
between maturational changes and polymor-
phisms comparing propofol and tramadol 
PK observations in early infancy. In essence, 
the utility of pharmacogenetics as predicting 
covariate is limited to periods during devel-
opment in which genotype-phenotype con-
cordance already exists [22, 47]. To illustrate 
this, a literature search on specific genetic 
polymorphisms related to PK/PD of analge-
sics in adults has been performed. Based on 
the findings of this search the relevance of 
specific genetic polymorphisms for optimiz-
ing analgesia in neonates will be explored.
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Maturational drug metabolism 
and polymorphisms: is  
“concordance” already present?
Besides age or weight as maturational 
covariates, genetic polymorphisms in drug-
metabolizing enzymes, transporters or recep-
tors may further contribute to the variability 
in PK/PD of analgesic drugs in early infancy 
if concordance already exists [23, 48]. Con-
cordance is hereby restricted to the presence 
of a phenotype-genotype linkage similar to 
what is known in adults. Sufficient matura-
tional driven phenotypic activity is needed 
before an impact of polymorphisms can be 
explored. We therefore try to illustrate this 
by comparing available observations on pro-
pofol and tramadol disposition [41, 42, 49].
Glucuronidation is the major meta-
bolic pathway after a single intravenous 
bolus of propofol in adults. As a conse-
quence,  UGT1A9 promotor polymorphisms 
( UGT1A9-331C/T) affect propofol clearance 
in adults [41]. However, this can’t be directly 
translated to the neonate because not gluc-
uronidation, but hydroxylation is the major 
route of propofol metabolic clearance in early 
neonatal life [43]. These in-vivo observations 
are in line with the available in vitro obser-
vations on UGT1A9 ontogeny describing a 
progressive increase in activity throughout 
infancy [50].
In contrast, concordance for the impact 
of cytochrome P450 enzyme 2D6 (CYP2D6) 
polymorphism on tramadol metabolism in 
early life has been described. Tramadol is a 
racemic mixture of two enantiomers, (+)-tra-
madol and (–)-tramadol hydrochloride [46, 
49]. The analgesic effects of tramadol are 
mediated through noradrenaline re-uptake 
inhibition, increased serotonin release and 
decreased serotonin re-uptake in the spi-
nal cord. Tramadol itself also has a weak 
 µ-opioid receptor effect. Tramadol (M) is 
metabolized by cytochrome P450 enzyme 
2D6 (CYP2D6) to the active metabolite 
(µ-opioid receptor agonist) O-desmethyl-
tramadol (M1) and the inactive metabolite 
N-desmethyltramadol (M2) through cyto-
chrome P450 3A4 and 2B6 (CYP3A4 and 
CYP2B6) [46, 49]. In adults, phenotypic 
M1 formation is more pronounced compared 
to M2 formation, but this ratio depends on 
CYP2D6 polymorphisms, quantified by the 
CYP2D6 activity score. Consequently, CY-
P2D6 polymorphisms result in differences 
in analgesia through differences in M1 for-
mation. Besides CYP2D6 polymorphisms, 
variability in M1 disposition has been linked 
to maturational changes (weight, age), come-
dication (e.g., drug-drug interactions) or co-
morbidity (e.g., renal impairment) [46, 49].
The complex interaction between matu-
rational changes and CYP2D6 polymor-
phisms in early infancy has been illustrated 
in a dataset of 57 cases exposed to continu-
ous intravenous tramadol [46, 49]. In this da-
taset, there was a significant decrease in plas-
ma log M/M1 with an increasing CYP2D6 
activity score, reflecting higher phenotypic 
CYP2D6 activity. In a forward multiple 
regression model, it was concluded that 
postmenstrual age and CYP2D6 polymor-
phisms determined O-demethylation activ-
ity in (pre)term neonates and young infants. 
Figure 2 illustrates the impact of both age 
(preterm vs. term cases) and CYP2D6 activ-
ity score (either 1, 2, or 3) on the plasma log 
M/M1 values, based on the earlier mentioned 
dataset in young infants [46, 49].
Figure 2. The impact of age (preterm (< 37 weeks) 
or term) and the CYP2D6 activity score (either 1, 2, 
or 3) on the plasma log M/M1 value. A lower M/M1 
value hereby reflects a higher CYP2D6 activity, de-
pending on both age and genetic polymorphisms. 
Individual plasma log M/M1 values were extract-
ed from an earlier published dataset on tramadol 
disposition in neonates. There were no cases with 
a CYP2D6 activity score of 3 in the preterm age 
cohort. (M = tramadol; M1 = O-desmethyltramadol) 
(X-axis: preterm (< 37 week) or term (≥ 37 week) 
cases, Y-axis: plasma log M/M1 value) [49].
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The absence of concordance for propofol 
but its presence for tramadol reflect differ-
ent patterns of maturational activity of spe-
cific isoenzymes with a much more delayed 
phenotypic activity for glucuronidation 
(UGT1A9) as compared to demethylation 
(CYP2D6). The utility of pharmacogenetics 
as predicting covariate is hereby limited to 
periods during development in which geno-
type-phenotype concordance already exists, 
and is mainly driven by observations initially 
reported in adults.
Are polymorphisms linked to 
the PK/PD of analgesics in 
adults already of relevance in 
perinatal life?
In this section we like to provide an over-
view of the impact of specific genetic poly-
morphisms linked to the PK/PD of analgesics 
in adults. Based on the findings of this search, 
the available evidence on the relevance of 
specific genetic polymorphisms to optimize 
analgesia in neonates will be explored. We 
will hereby consider polymorphisms related 
to drug metabolizing enzymes, drug trans-
porters, and drug targets.
Drug-metabolizing enzymes
Inter-individual variability exists in both 
phase I and phase II drug metabolism, and 
this variability can in part be explained by 
genetic polymorphisms. It may result in dif-
ferences in either effects (e.g., concentra-
tions, level of analgesia) or sideeffects (e.g., 
sedation, toxicity).
The tramadol illustration earlier men-
tioned hereby provides the impact of 
 CYP2D6 polymorphism on metabolic clear-
ance to M1 in neonates, in line with simi-
lar observations in adults for tramadol or 
codeine [46, 49]. In the specific setting of 
breastfeeding, maternal CYP2D6 ultrafast 
metabolizer status – especially when com-
bined with UGT2B7 *2/*2 polymorphism – 
results in higher exposure and an increased 
risk for central nervous system depression 
[51]. In contrast, CYP2C8 and CYP2C9 
polymorphisms could not explain the vari-
ability in patent ductus closure during ibu-
profen administration in preterm neonates 
[52]. Similarly, CYP2C8 and CYP2C9 poly-
morphisms had no effect on the relative in-
fant dose (all < 1%) through breastfeeding in 
mothers treated with ibuprofen [53]. An as-
sociation between CYP3A5 polymorphisms 
(higher drug metabolism) and paracetamol-
induced liver toxicity has been described 
in adults [54]. This is unlikely in neonates, 
because the overall phenotypic CYP3A5 in 
early infancy is much lower [20, 21, 22].
If we further focus on phase II process-
es, Matic et al. [55] recently described the 
impact of UGT2B7 polymorphisms on the 
morphine-3-glucuronide/morphine ratio fol-
lowing a single bolus administration of mor-
phine (0.3 mg/kg) in preterm neonates. Since 
sulphation activity is already more promi-
nent, it seems more appropriate to explore 
these polymorphisms. Sulphotransferase en-
zymes catalyze sulphate conjugation, includ-
ing paracetamol sulphation. As explored by 
Leeder et al. [48], exposure to paracetamol 
during pregnancy has been associated with 
a modest increase in the risk (RR 1.5 – 1.7) 
of gastroschisis in the infant. Based on in-
vitro liver cytosol preparations, it has been 
suggested that paracetamol sulphation by 
the fetus might be linked with this increased 
incidence of gastroschisis. Clearly, further 
investigations into the genetic variability in 
both maternal (SULT1A1, SULT2A1) and 
fetal (SULT1A3/4) sulfation might shed 
more light on this association [48].
Drug transporters
Membrane transporters are crucial in the 
transport of compounds, and subsequently 
also mediate the uptake, regional distribu-
tion, and excretion of different compounds, 
including analgesics and its metabolites. 
Compared to the knowledge on the ontog-
eny of drug metabolizing enzymes, data on 
the maturation of human drug transporter 
expression and activity is still much more 
limited, but was recently summarized [47]. 
In fact, these authors also suggest to explore 
pharmacogenetic concordance in early infan-
cy and other age cohorts to learn more about 
their ontogeny.
The maturational changes in expression 
and activity of P-glycoprotein (P-gp) may 
affect the ability of the neonate to efflux opi-
Allegaert and van den Anker 520
oids from the central nervous system com-
partment back to the systemic circulation. 
This may in part explain the higher sensitiv-
ity to central nervous system depressive ef-
fects of opioids in neonates. To quantify P-gp 
expression and its ontogeny, post-mortem 
samples (20 weeks fetal age to adults) were 
immunostained for P-gp in endothelial cells 
of the blood-brain barrier [56]. The authors 
hereby documented a maturational expres-
sion in P-gp to reach adult levels beyond 
3 months of age. This ontogenic pattern fits 
quite well with the observations that P-gp 
polymorphisms (ABCB1 polymorphism 
rs9282564) were associated with a higher 
risk of opioid-related respiratory depression 
in children, but not anymore in adults, and 
not yet in neonates [57]. Adding one copy of 
the minor allele increased the odds of pro-
longed stay to the respiratory depression 4.7 
fold. This suggests extensive placental P-gp 
expression, confirmed by the observation 
that fetal P-gp polymorphisms affect fetal 
growth and birth weight [58]. Finally, and 
to illustrate the complex interaction between 
different covariates, Sistonen et al. [59] 
documented that a genetic model combin-
ing the maternal risk genotypes in CYP2D6 
and P-gp was significantly associated with 
central nervous system depression in infants 
(OR 2.68) and their mothers (OR 2.74) dur-
ing maternal codeine intake.
Drug targets
Similar to drug transporters, the knowl-
edge on the ontogeny of drug receptors or 
drug targets is very limited. Again, a search 
for concordance in early infancy for poly-
morphisms earlier documented in adults 
hereby provides clinical information on the 
phenotypic expression and activity. In the 
field of analgesia, we retrieved mainly re-
ports on polymorphisms of the µ-opioid re-
ceptor (OPRM1), sometimes in combination 
with catechol-O-methyl transferase (COMT) 
polymorphisms. The combination of both 
(OPRM1/COMT) results in synergistic ef-
fects since the need for rescue morphine in 
mechanically ventilated newborns was asso-
ciated with both polymorphisms, resulting in 
an OR of 5.12 in the OPRM1/COMT high-
risk genotype [60]. This is line with findings 
reported in children following adenotonsil-
lectomy, since COMT polymorphisms also 
played a significant role in the variation in 
postoperative pain perception and postopera-
tive morphine requirements in children [61].
Clinical practice and research: 
in search for the Holy Grail
Effective pain management remains an 
important indicator of the quality of care pro-
vided to neonates, but observations on neu-
roapoptosis and integration of newer tech-
niques and compounds force caregivers to 
reconsider the clinical and research aspects 
of “effective” pain management.
In the clinical setting, a structured ap-
proach is needed. This is because there is 
still a gap between what we know and how 
we act [19, 62]. An effective approach (e.g., 
evidence-based practice for improving qual-
ity (EPIQ) initiative) has been described by 
Dunbar et al. [63]. Twelve NICU’s collabo-
rated to improve neonatal pain and sedation 
practices. In essence, these units developed 
and subsequently implemented evidence-
based better practices for pain management 
in neonates, using such an EPIQ approach 
[63, 64]. At the start, all units introduced 
changes through plan-do-study-act cycles 
and verified their performance. Strategies 
for implementing potentially better prac-
tices varied and units identified their barri-
ers to implementation, developed tools for 
improvement, and subsequently shared their 
experience. This approach of collaborative 
quality improvement techniques enhanced 
local quality improvement efforts and result-
ed in effective implementation of potentially 
better practices in all centers [65, 66]. Re-
search to further improve the knowledge on 
pain management is obviously also needed. 
Using a bullet point approach, we suggest 
that such a research agenda covers:
 – Robust pharmacodynamic outcome vari-
ables are needed [18]. The development 
and validation of more sophisticated pain 
assessment tools is needed. At present, 
we measure at the level of pain expres-
sion and that is not equal to pain percep-
tion.
 – PK/PD information on new compounds 
can be generated. However, pharmaco-
vigilance and long-term outcome data 
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are needed after perinatal exposure to an-
algesics. This should include, but cannot 
be limited to, neurocognitive outcome [2, 
7, 8, 22].
 – Clinicians, ethical committees and other 
stakeholders should design dose-finding 
studies aimed at improving adequate 
(i.e., effective, no over- or underexpo-
sure) administration of analgesics in neo-
nates. The animal experimental findings 
on neuro-apoptosis force us to reconsider 
drugs and doses currently administered in 
NICUs across the world.
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